QCG
LENZ

Quadrant Capital Group’s LENZ Therapeutics LENZ Stock Holding History

Quadrant Capital Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27
Closed -$695 – 2689
2025
Q1 		$695 Buy
+27
New +$665 ﹤0.01% 2617

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrant Capital Group's LENZ Position: Q2 2025 in Review

Quadrant Capital Group sold out of LENZ Therapeutics (LENZ) in Q2 2025, closing a stake of 27 shares — an estimated $695 sold.

Quadrant Capital Group first reported a position in LENZ in Q1 2025 and held it in 1 quarter. The position peaked at $695 in Q1 2025. 113 funds tracked by Wall St. Rank hold LENZ as of Q2 2025.

  • Quadrant Capital Group reported no remaining LENZ Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 27 LENZ Therapeutics shares in Q2 2025, an estimated $695.
  • Quadrant Capital Group first reported a position in LENZ Therapeutics in Q1 2025 and held it in 1 quarter.
  • Quadrant Capital Group's LENZ Therapeutics position peaked at $695 in Q1 2025.
  • 113 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.